Cargando…
Advancement of secretory breast carcinoma: a narrative review
BACKGROUND AND OBJECTIVE: Secretory breast carcinoma (SBC) is a rare breast malignancy. Most available studies on SBC are case reports or small case series, and the few large-sample studies available lack critical information due to database limitations. To improve the understanding of SBC and provi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708487/ https://www.ncbi.nlm.nih.gov/pubmed/36467350 http://dx.doi.org/10.21037/atm-22-2491 |
_version_ | 1784840945083088896 |
---|---|
author | Min, Ningning Zhu, Jingjin Liu, Mei Li, Xiru |
author_facet | Min, Ningning Zhu, Jingjin Liu, Mei Li, Xiru |
author_sort | Min, Ningning |
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: Secretory breast carcinoma (SBC) is a rare breast malignancy. Most available studies on SBC are case reports or small case series, and the few large-sample studies available lack critical information due to database limitations. To improve the understanding of SBC and provide a reference for clinical practice, we systematically reviewed the demographic, clinical, pathologic, and genetic characteristics of SBC, as well as its treatment and prognosis. METHODS: We conducted a PubMed search with the keywords “secretory breast carcinoma” or “juvenile breast carcinoma”. Relevant English-language publications published from January 1966 to February 2022 were screened manually at 3 levels—title, abstract, and full text—to identify the articles that presented the demographic, clinical, pathologic, and genetic characteristics of SBC, as well as its treatment and prognosis. KEY CONTENT AND FINDINGS: SBC lacks specific clinical manifestations and has typical pathological and molecular characteristics, including intracellular and extracellular eosinophilic secretions, immune spectrum similar to hormone receptor-positive tumors, and the ETV6-NTRK3 fusion gene. Surgery remains the primary treatment for SBC. Postoperative radiotherapy is recommended by most researchers for adult SBC but not for pediatric patients. The evidence of chemotherapy and endocrine therapy is insufficient, and targeted therapy of the ETV6-NTRK3 fusion gene shows a good response. Most patients with SBC have a good prognosis except for a few patients who experience distant metastases. Future studies will be focused on the molecular characteristics of those patients with SBC who have a poor prognosis. CONCLUSIONS: The development of histopathology and molecular genetics has promoted the progress of the clinical diagnosis of SBC. The purpose of this review is to serve as a guide for the better clinical treatment of SBC, particularly in the areas of disease identification and prognosis classification for patients. |
format | Online Article Text |
id | pubmed-9708487 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-97084872022-12-01 Advancement of secretory breast carcinoma: a narrative review Min, Ningning Zhu, Jingjin Liu, Mei Li, Xiru Ann Transl Med Review Article BACKGROUND AND OBJECTIVE: Secretory breast carcinoma (SBC) is a rare breast malignancy. Most available studies on SBC are case reports or small case series, and the few large-sample studies available lack critical information due to database limitations. To improve the understanding of SBC and provide a reference for clinical practice, we systematically reviewed the demographic, clinical, pathologic, and genetic characteristics of SBC, as well as its treatment and prognosis. METHODS: We conducted a PubMed search with the keywords “secretory breast carcinoma” or “juvenile breast carcinoma”. Relevant English-language publications published from January 1966 to February 2022 were screened manually at 3 levels—title, abstract, and full text—to identify the articles that presented the demographic, clinical, pathologic, and genetic characteristics of SBC, as well as its treatment and prognosis. KEY CONTENT AND FINDINGS: SBC lacks specific clinical manifestations and has typical pathological and molecular characteristics, including intracellular and extracellular eosinophilic secretions, immune spectrum similar to hormone receptor-positive tumors, and the ETV6-NTRK3 fusion gene. Surgery remains the primary treatment for SBC. Postoperative radiotherapy is recommended by most researchers for adult SBC but not for pediatric patients. The evidence of chemotherapy and endocrine therapy is insufficient, and targeted therapy of the ETV6-NTRK3 fusion gene shows a good response. Most patients with SBC have a good prognosis except for a few patients who experience distant metastases. Future studies will be focused on the molecular characteristics of those patients with SBC who have a poor prognosis. CONCLUSIONS: The development of histopathology and molecular genetics has promoted the progress of the clinical diagnosis of SBC. The purpose of this review is to serve as a guide for the better clinical treatment of SBC, particularly in the areas of disease identification and prognosis classification for patients. AME Publishing Company 2022-11 /pmc/articles/PMC9708487/ /pubmed/36467350 http://dx.doi.org/10.21037/atm-22-2491 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Review Article Min, Ningning Zhu, Jingjin Liu, Mei Li, Xiru Advancement of secretory breast carcinoma: a narrative review |
title | Advancement of secretory breast carcinoma: a narrative review |
title_full | Advancement of secretory breast carcinoma: a narrative review |
title_fullStr | Advancement of secretory breast carcinoma: a narrative review |
title_full_unstemmed | Advancement of secretory breast carcinoma: a narrative review |
title_short | Advancement of secretory breast carcinoma: a narrative review |
title_sort | advancement of secretory breast carcinoma: a narrative review |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708487/ https://www.ncbi.nlm.nih.gov/pubmed/36467350 http://dx.doi.org/10.21037/atm-22-2491 |
work_keys_str_mv | AT minningning advancementofsecretorybreastcarcinomaanarrativereview AT zhujingjin advancementofsecretorybreastcarcinomaanarrativereview AT liumei advancementofsecretorybreastcarcinomaanarrativereview AT lixiru advancementofsecretorybreastcarcinomaanarrativereview |